Literature DB >> 28409903

Primary, secondary and compensated hypogonadism: a novel risk stratification for infertile men.

E Ventimiglia1,2, S Ippolito1,2, P Capogrosso1,2, F Pederzoli1, W Cazzaniga1,2, L Boeri1, I Cavarretta1, M Alfano2, P Viganò3, F Montorsi1,2, A Salonia1,2.   

Abstract

Recently, the cohort of men from the European Male Ageing Study has been stratified into different categories distinguishing primary, secondary and compensated hypogonadism. A similar classification has not yet been applied to the infertile population. We performed a cross-sectional study enrolling 786 consecutive Caucasian-European infertile men segregated into eugonadal [normal serum total testosterone (≥3.03 ng/mL) and normal luteinizing hormone (≤9.4 mU/mL)], secondary (low total testosterone, low/normal luteinizing hormone), primary (low total testosterone, elevated luteinizing hormone) and compensated hypogonadism (normal total testosterone; elevated luteinizing hormone). In this cross-sectional study, logistic regression models tested the association between semen parameters, clinical characteristics and the defined gonadal status. Eugonadism, secondary, primary and compensated hypogonadism were found in 80, 15, 2, and 3% of men respectively. Secondary hypogonadal men were at highest risk for obesity [OR (95% CI): 3.48 (1.98-6.01)]. Primary hypogonadal men were those at highest risk for azoospermia [24.54 (6.39-161.39)] and testicular volume <15 mL [12.80 (3.40-83.26)]. Compensated had a similar profile to primary hypogonadal men, while their risk of azoospermia [5.31 (2.25-13.10)] and small testicular volume [8.04 (3.17-24.66)] was lower. The risk of small testicular volume [1.52 (1.01-2.33)] and azoospermia [1.76 (1.09-2.82)] was increased, although in a milder fashion, in secondary hypogonadal men as well. Overall, primary and compensated hypogonadism depicted the worst clinical picture in terms of impaired fertility. Although not specifically designed for infertile men, European Male Ageing Study categories might serve as a clinical stratification tool even in this setting.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  azoospermia; gonadal status; hypogonadism; male infertility

Mesh:

Year:  2017        PMID: 28409903     DOI: 10.1111/andr.12335

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  9 in total

1.  Leukocytospermia is not an informative predictor of positive semen culture in infertile men: results from a validation study of available guidelines.

Authors:  Eugenio Ventimiglia; Paolo Capogrosso; Luca Boeri; Walter Cazzaniga; Rayan Matloob; Edoardo Pozzi; Francesco Chierigo; Costantino Abbate; Paola Viganò; Francesco Montorsi; Andrea Salonia
Journal:  Hum Reprod Open       Date:  2020-09-22

2.  Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism.

Authors:  David Møbjerg Kristensen; Christèle Desdoits-Lethimonier; Abigail L Mackey; Marlene Danner Dalgaard; Federico De Masi; Cecilie Hurup Munkbøl; Bjarne Styrishave; Jean-Philippe Antignac; Bruno Le Bizec; Christian Platel; Anders Hay-Schmidt; Tina Kold Jensen; Laurianne Lesné; Séverine Mazaud-Guittot; Karsten Kristiansen; Søren Brunak; Michael Kjaer; Anders Juul; Bernard Jégou
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  Testicular ultrasound inhomogeneity is an informative parameter for fertility evaluation.

Authors:  Giorgia Spaggiari; Antonio R M Granata; Daniele Santi
Journal:  Asian J Androl       Date:  2020 May-Jun       Impact factor: 3.285

4.  Clinical correlation among male infertility and overall male health: A systematic review of the literature.

Authors:  Francesco Del Giudice; Alex M Kasman; Matteo Ferro; Alessandro Sciarra; Ettore De Berardinis; Federico Belladelli; Andrea Salonia; Michael L Eisenberg
Journal:  Investig Clin Urol       Date:  2020-06-08

5.  Testicular ultrasound score: A new proposal for a scoring system to predict testicular function.

Authors:  Carlotta Pozza; George Kanakis; Francesco Carlomagno; Andrea Lemma; Riccardo Pofi; Marta Tenuta; Marianna Minnetti; Maria G Tarsitano; Franz Sesti; Donatella Paoli; Antonella Anzuini; Andrea Lenzi; Andrea M Isidori; Daniele Gianfrilli
Journal:  Andrology       Date:  2020-07-02       Impact factor: 3.842

6.  Extensive Assessment of Underlying Etiological Factors in Primary Infertile Men Reduces the Proportion of Men With Idiopathic Infertility.

Authors:  Eugenio Ventimiglia; Edoardo Pozzi; Paolo Capogrosso; Luca Boeri; Massimo Alfano; Walter Cazzaniga; Rayan Matloob; Costantino Abbate; Paola Viganò; Francesco Montorsi; Andrea Salonia
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

7.  From subjective to objective: A pilot study on testicular radiomics analysis as a measure of gonadal function.

Authors:  Bruno De Santi; Giorgia Spaggiari; Antonio Rm Granata; Marilina Romeo; Filippo Molinari; Manuela Simoni; Daniele Santi
Journal:  Andrology       Date:  2021-12-09       Impact factor: 4.456

8.  Anti-Mullerian Hormone-to-Testosterone Ratio is Predictive of Positive Sperm Retrieval in Men with Idiopathic Non-Obstructive Azoospermia.

Authors:  Massimo Alfano; Eugenio Ventimiglia; Irene Locatelli; Paolo Capogrosso; Walter Cazzaniga; Filippo Pederzoli; Nicola Frego; Rayan Matloob; Antonino Saccà; Luca Pagliardini; Paola Viganò; Pietro Zerbi; Manuela Nebuloni; Marina Pontillo; Francesco Montorsi; Andrea Salonia
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

9.  Testicular volume in infertile versus fertile white-European men: a case-control investigation in the real-life setting.

Authors:  Luca Boeri; Paolo Capogrosso; Eugenio Ventimiglia; Walter Cazzaniga; Edoardo Pozzi; Federico Belladelli; Filippo Pederzoli; Massimo Alfano; Costantino Abbate; Emanuele Montanari; Luca Valsecchi; Enrico Papaleo; Paola Viganò; Patrizia Rovere-Querini; Suks Minhas; Francesco Montorsi; Andrea Salonia
Journal:  Asian J Androl       Date:  2021 Sep-Oct       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.